Evidence map›Paper›PMID 41641545›Full record

ArticleArteriosclerosis, thrombosis, and vascular biology2026

Single-Cell Multimodal Profiling Highlights Persistent Aortic Smooth Muscle Cell Changes in Diabetic Mice Despite Glycemic Control.

Vinay Singh Tanwar, Vajir Malek, Jingyi Wang, Yingjun Luo, Naseeb Kaur Malhi, Hongpan Zhang, Maryam Abdollahi, Linda Lanting, Parijat Senapati, Sadhan Das and 5 more

Abstract read
In one paragraph

Article in Arteriosclerosis, thrombosis, and vascular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Vinay Singh Tanwar *Department of Diabetes Complications and Metabolism, Arthur Riggs Diabetes and Metabolism Research Institute (V.S.T., V.M., Y.L., N.K.M., M.A., L.L., M.A.R., Z.B.C., R.N.), Beckman Research Institute of City of Hope, Duarte, CA.ORCID 0000-0001-6168-2752
Vajir Malek *Department of Diabetes Complications and Metabolism, Arthur Riggs Diabetes and Metabolism Research Institute (V.S.T., V.M., Y.L., N.K.M., M.A., L.L., M.A.R., Z.B.C., R.N.), Beckman Research Institute of City of Hope, Duarte, CA.ORCID 0000-0003-3680-058X
Jingyi Wang *Department of Genome Sciences, University of Virginia, Charlottesville (J.W., H.Z., C.Z., C.L.M.).ORCID 0000-0003-4963-2482
Yingjun LuoDepartment of Diabetes Complications and Metabolism, Arthur Riggs Diabetes and Metabolism Research Institute (V.S.T., V.M., Y.L., N.K.M., M.A., L.L., M.A.R., Z.B.C., R.N.), Beckman Research Institute of City of Hope, Duarte, CA.ORCID 0000-0003-2271-3725
Naseeb Kaur MalhiDepartment of Diabetes Complications and Metabolism, Arthur Riggs Diabetes and Metabolism Research Institute (V.S.T., V.M., Y.L., N.K.M., M.A., L.L., M.A.R., Z.B.C., R.N.), Beckman Research Institute of City of Hope, Duarte, CA.ORCID 0000-0002-8981-2974
Hongpan ZhangDepartment of Genome Sciences, University of Virginia, Charlottesville (J.W., H.Z., C.Z., C.L.M.).ORCID 0000-0003-0932-176X
Maryam AbdollahiDepartment of Diabetes Complications and Metabolism, Arthur Riggs Diabetes and Metabolism Research Institute (V.S.T., V.M., Y.L., N.K.M., M.A., L.L., M.A.R., Z.B.C., R.N.), Beckman Research Institute of City of Hope, Duarte, CA.ORCID 0000-0002-1989-6068
Linda LantingDepartment of Diabetes Complications and Metabolism, Arthur Riggs Diabetes and Metabolism Research Institute (V.S.T., V.M., Y.L., N.K.M., M.A., L.L., M.A.R., Z.B.C., R.N.), Beckman Research Institute of City of Hope, Duarte, CA.
Parijat SenapatiCancer Research Division, BRIC-Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, Kerala, India (P.S.).ORCID 0000-0002-7324-1230
Sadhan DasDepartment of Biological Sciences, Indian Institute of Science Education and Research, Mohali, Punjab, India (S.D.).ORCID 0000-0002-7153-9519
Marpadga A ReddyDepartment of Diabetes Complications and Metabolism, Arthur Riggs Diabetes and Metabolism Research Institute (V.S.T., V.M., Y.L., N.K.M., M.A., L.L., M.A.R., Z.B.C., R.N.), Beckman Research Institute of City of Hope, Duarte, CA.ORCID 0000-0001-9259-7243
Chongzhi ZangDepartment of Genome Sciences, University of Virginia, Charlottesville (J.W., H.Z., C.Z., C.L.M.).ORCID 0000-0003-4812-3627
Clint L MillerDepartment of Genome Sciences, University of Virginia, Charlottesville (J.W., H.Z., C.Z., C.L.M.).ORCID 0000-0003-4276-3607
Zhen Bouman ChenDepartment of Diabetes Complications and Metabolism, Arthur Riggs Diabetes and Metabolism Research Institute (V.S.T., V.M., Y.L., N.K.M., M.A., L.L., M.A.R., Z.B.C., R.N.), Beckman Research Institute of City of Hope, Duarte, CA.ORCID 0000-0002-3291-1090
Rama NatarajanDepartment of Diabetes Complications and Metabolism, Arthur Riggs Diabetes and Metabolism Research Institute (V.S.T., V.M., Y.L., N.K.M., M.A., L.L., M.A.R., Z.B.C., R.N.), Beckman Research Institute of City of Hope, Duarte, CA.ORCID 0000-0003-4494-1788

Funding

Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI John Charles Williams · 1985 to 2026
$86.3M
Inflammatory Gene Transcription In Diabetic ConditionsR01DK065073 · NIDDK · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI NATARAJAN, RAMA · 2003 to 2021
$7.9M
Transcriptional Regulation by Angiotensin II in Vascular Smooth Muscle CellsR01HL106089 · NHLBI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI NATARAJAN, RAMA · 2011 to 2024
$6.6M
Transforming growth factor beta1, microRNAs, lncRNA and diabetic nephropathyR01DK081705 · NIDDK · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI NATARAJAN, RAMA · 2009 to 2023
$6.1M
Multimodal genetic regulatory architecture of coronary artery diseaseR01HL148239 · NHLBI · UNIVERSITY OF VIRGINIA · PI Clint L Miller · 2019 to 2026
$4.2M
Integrative computational models for functional epigenomics and transcriptional regulationR35GM133712 · NIGMS · UNIVERSITY OF VIRGINIA · PI Chongzhi Zang · 2019 to 2026
$3.4M
Molecular Drivers of Atherosclerosis in DiabetesU01DK142283 · NIDDK · UNIVERSITY OF VIRGINIA · PI Mete Civelek, Clint L Miller · 2024 to 2026
$2.9M
Functional genomics investigation of pleiotropic vascular disease lociR01HL164577 · NHLBI · UNIVERSITY OF VIRGINIA · PI MILLER, CLINT L · 2022 to 2025
$2.3M
RNA-mediated endotheliopathy in diabetic vasculopathyR35HL171550 · NHLBI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI Zhen Bouman Chen · 2024 to 2026
$2.2M
Chromatin remodeling factors and mechanisms in diabetic microvascular complicationsR01DK143577 · NIDDK · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI Zhen Bouman Chen, RAMA NATARAJAN · 2025 to 2026
$1.5M
NCI NIH HHS P30 CA033572NHLBI NIH HHS R01 HL106089NHLBI NIH HHS R01 HL148239NHLBI NIH HHS R01 HL164577NHLBI NIH HHS R35 HL171550NIDDK NIH HHS R01 DK065073NIDDK NIH HHS R01 DK081705NIDDK NIH HHS R01 DK143577NIDDK NIH HHS U01 DK142283NIGMS NIH HHS R35 GM133712
6 · The paper itself

Abstract

backgroundType 2 diabetes is associated with accelerated vascular complications such as hypertension and atherosclerosis. Phenotypic switching of vascular smooth muscle cells (SMCs), a major driver of these complications, is enhanced in diabetes. Despite adequate glycemic control, SMC dysfunction can persist due to metabolic memory of prior hyperglycemia. However, the mechanisms are unclear. Here, leveraging single-cell multiomics, we examined the effect of glucose normalization on transcriptomic and epigenomic changes associated with SMC phenotypic transition in type 2 diabetes mice.

methodsType 2 diabetes db/db mice were treated with the antidiabetic drug dapagliflozin (DAPA) or vehicle and nondiabetic control db/+ mice with vehicle for 6 weeks. Dissected aortas were subjected to single-cell RNA sequencing, single-cell assay for transposase-accessible chromatin with sequencing, and spatial transcriptomics (Xenium) to determine single-cell changes in gene expression and chromatin accessibility.

resultsDAPA conferred effective glycemic control in db/db mice, with significant reductions in blood glucose and hemoglobinA1c. scRNA and single-cell assay for transposase-accessible chromatin with sequencing analysis of aortas identified SMC, fibroblasts, endothelial, and immune cells. SMCs were further clustered into 9 subtypes, including contractile and fibromyocyte-like cells. Interestingly, SMC contractile phenotype-associated pathways decreased in diabetes and remained decreased despite DAPA treatment. Fibrosis and inflammation-associated pathways in SMC and fibroblasts, and dysfunction markers in endothelial cells, increased in diabetes and were partly reversed by DAPA. Pseudotime trajectory analysis of SMC revealed increased activities of fibromyocyte-enriched TFs (transcription factors) during the contractile to fibromyocyte transition. Pairwise analysis for differentially accessible regions revealed diabetes-associated differentially accessible regions, enrichment of TF motifs, and related disease-associated biological processes. However, no differentially accessible regions were identified between db/db and db/dbDAPA groups. Spatial transcriptomics mapped aortic cell types within intact aortas and validated single-cell sequencing data.

conclusionsType 2 diabetes induces gene expression and chromatin accessibility changes associated with profound SMC phenotypic switching. These changes are not efficiently reversed by a widely used antidiabetic drug, DAPA, underscoring the need for more effective therapies targeting hyperglycemic memory.

Indexed as

aortacardiovascular diseasesdiabetes mellitus, type 2epigenomicsglycemic controlmultiomicssodium-glucose transporter 2 inhibitors

Identifiers

PMID41641545
PMCPMC12916121

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.